Analyst Price Targets — PCRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 1, 2026 11:40 am | — | Needham | $32.00 | $25.49 | TheFly | Pacira price target raised to $32 from $30 at Needham |
| December 8, 2025 9:27 pm | — | Barclays | $27.00 | $24.42 | TheFly | Pacira initiated with an Equal Weight at Barclays |
| February 28, 2025 6:37 pm | — | Barclays | $24.00 | $24.05 | TheFly | Pacira price target raised to $24 from $17 at Barclays |
| February 28, 2025 11:11 am | — | H.C. Wainwright | $48.00 | $24.05 | TheFly | Pacira price target raised to $48 from $39 at H.C. Wainwright |
| January 30, 2025 11:03 am | Les Sulewski | Truist Financial | $25.00 | $26.03 | StreetInsider | Truist Securities Upgrades Pacira Pharmaceuticals (PCRX) to Buy |
| November 7, 2024 12:42 pm | David Amsellem | Piper Sandler | $12.00 | $17.37 | StreetInsider | Pacira Pharmaceuticals (PCRX) PT Raised to $12 at Piper Sandler |
| September 24, 2024 9:32 am | Glen Santangelo | Jefferies | $18.00 | $14.77 | StreetInsider | Pacira Pharmaceuticals (PCRX) PT Raised to $18 at Jefferies |
| August 13, 2024 6:08 am | Les Sulewski | Truist Financial | $8.00 | $12.29 | TheFly | Pacira downgraded to Sell from Buy at Truist |
| July 2, 2024 12:36 pm | Oren Livnat | H.C. Wainwright | $57.00 | $21.91 | TheFly | Pacira should be bought on today's selloff, says H.C. Wainwright |
| June 13, 2024 11:57 am | Glen Santangelo | Jefferies | $36.00 | $28.50 | StreetInsider | Jefferies Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX) |
Latest News for PCRX
BRISBANE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2026 to ten new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's…
PCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on biopharmaceutical growth.
-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that UnitedHealthcare now provides separate reimbursement for EXPAREL® (bupivacaine…
-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments -- -- Two companies will collaborate on advancing the spasticity program --
BRISBANE, Calif., June 9, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that based on the preliminary results of its 2026 Annual Meeting of Stockholders (the "Annual Meeting") provided by its proxy solicitor, D.F.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PCRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.